Alexa Kimball
Beth Israel Deaconess Medical Center · Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexa Kimball as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:11 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03791060 · Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)Beth Israel Deaconess Medical Center · terminated · Necrobiosis Lipoidica Diabeticorum · principal investigator
- Ph2/Ph3NCT00823901 · Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat RosaceaMassachusetts General Hospital · completed · Rosacea · principal investigator
- N/ANCT00823914 · Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of LifeMassachusetts General Hospital · completed · Psoriasis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:11 UTC. The ranking covers the 200 most relevant of 116 PubMed records, and a shared surname and initials can bring in a namesake. All 116 on PubMed
- 1,313 citationsRCR 33.5
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.J Am Acad Dermatol · 2008704 citationsRCR 20.1
- 704 citationsRCR 30.5
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.N Engl J Med · 2015675 citationsRCR 25.2
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.N Engl J Med · 2016623 citationsRCR 26.5
- 465 citationsRCR 19.0
- Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.Ann Intern Med · 2012342 citationsRCR 13.3
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.Lancet Oncol · 2017337 citationsRCR 11.0
- 272 citationsRCR 39.9
- Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.Br J Dermatol · 2014175 citationsRCR 8.2